Antonijevic Nebojsa, Stanojevic Milica, Milosevic Rajko, Djordjevic Valentina, Jaukovic Milena, Vukcevic Vlada, Kovac Mirjana, Mikovic Danijela, Radojkovic Dragica, Vasiljevic Zorana
Institute of Cardiovascular Diseases, Clinical Centre of Serbia, Pasterova 2, Belgrade, Serbia and Montenegro.
J Thromb Thrombolysis. 2005 Apr;19(2):93-5. doi: 10.1007/s11239-005-0783-1.
We present the case of a 64 year-old female patient, with a clearly positive family history of venous thromboembolism (VTE), multiple VTE episodes (massive pulmonary embolism, ovarian venous plexus thrombosis, deep venous thrombosis with submassive pulmonary embolism and second deep venous thrombosis) and myocardial infarction. Laboratory tests revealed the resistance to the activated protein C, elevated FVIII and PAI-1. The patient was found to be a heterozygous carrier of FV Leiden, MTHFR C677T and PAI-1 4G/5G mutations. She was diagnosed with essential thrombocythemia at the age of 60. The thirty-three-year follow-up of our patient and detection of recurrent thrombotic episodes in the light of multiple coagulation defects with proved acquired risk factors, contributes to the risk stratification in the group of patients with very high risk. In case of our patient, we stress inadequacy of widely-accepted standard prevention measures. In our opinion, patients with very high risk require additional mechanic and specific medicament methods of VTE prevention.
我们报告了一例64岁女性患者的病例,该患者有明确的静脉血栓栓塞症(VTE)家族史,发生过多次VTE事件(大面积肺栓塞、卵巢静脉丛血栓形成、伴有次大面积肺栓塞的深静脉血栓形成和第二次深静脉血栓形成)以及心肌梗死。实验室检查显示对活化蛋白C有抵抗,FVIII和PAI-1升高。该患者被发现是FV Leiden、MTHFR C677T和PAI-1 4G/5G突变的杂合子携带者。她在60岁时被诊断为原发性血小板增多症。对我们患者进行的33年随访以及鉴于存在已证实的获得性危险因素的多种凝血缺陷而检测到复发性血栓形成事件,有助于对极高风险患者组进行风险分层。就我们的患者而言,我们强调广泛接受的标准预防措施并不充分。我们认为,极高风险患者需要额外的机械和特定药物方法来预防VTE。